Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

Leap Therapeutics' Phase 2 trial data show sirexatamab boosts response rates and survival in MSS colorectal cancer, with ...

Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

atezolizumab and bevacizumab, the standard of care, in patients with unresectable or metastatic HCC treated in the first line ...

Tempest Therapeutics (NASDAQ:TPST) shares dropped Thursday after the company updated data from ... advantage with cancer drugs atezolizumab and bevacizumab, marketed as Tecentriq and Avastin ...

The company maintains that off-label bevacizumab is not held to ophthalmic quality standards, with variable potency, recalls and compliance issues, and adverse events. "Many ophthalmologists have ...

Company has one year of cash to fund operations Company advancing plans to develop TPI 287, a novel, late stage abeotaxane ...

Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC)• Announced Agreement with Roche to Support Advancement of ...

Detailed price information for Outlook Therapeutics Inc (OTLK-Q) from The Globe and Mail including charting and trades.

By 2023, approximately 1 in 5 patients with non-small cell lung cancer or metastatic colorectal cancer were treated with a bevacizumab biosimilar.

Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFS in second-line CRC patients with high DKK1 levels treated with sirexatamab plus ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...